THE NEXT GENERATION IN REMOTE PATIENT MONITORING
Advances in Personalized Medicine and Digital Health technologies are revolutionizing modern medicine. NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
Port efficacy + new sensor technology
Remotely measure real-time physiological distress
Digital health platform coordinating patients + providers
COSTS $2.3 BILLION ANNUALLY
Of patients on chemo with a port suffer from neutropenia which puts them at greater risk for infection and complications
Of patients have complications ranging from minor to major, most frequently infections and thrombosis, leading to port removal, hospitalization, higher medical costs and treatment
Of women on trastuzumab for HER2+ breast cancer suffer cardiotoxicity and cardiac function decline
Of patients have to delay or cancel treatment due to poor blood counts on treatment days
Physiologic changes and trends measured in vivo.
DATA + ANALYTICS
Real-time information about a patient's health status.
REPORT TO PROVIDER
Relevant measures and actionable data.
Virtual patient management.
NXgen Port PROVIDES EARLY
Changes in heart function
Blood cells counts
Proteins (i.e., hemoglobin)
Device leakage or failure
Early indication of infection
Remote patient monitoring
Put “eyes and hands” on patients
Maximize clinic time
Baseline of health before treatment begins
Awareness of acceptable symptoms
Alert to infection Peace of mind
Reduce unexpected hospitalizations
Manage costs due to adverse events
Reduce treatment cancelations or delays
Manage costs Increase efficiency
Virtual clinical trial support
Passive data collection
Adherence and drug efficacy
Cathy Skinner, MA
Chief Executive Officer
Entrepreneur with 12 years of startup experience (Thrivors.com and TheArtofWell.com).
Nationally recognized Cancer Exercise Specialist with the American College of Sports Medicine.
12 years of working face-to-face with cancer patients and survivors providing wellness programs.
Invited panelist and guest speaker, Cancer Survivorship Conferences, Employer Benefits, Pharma Patient Advocacy conferences.
Former Chair of the Minnesota Cancer Alliance.
Board member with one non-profit organization.
Rosanne Welcher, PhD, MBA, RAC
Chief Operating Officer
Award-winning R&D and Business Leader with cross-functional expertise in Medical Devices/IVD business development, product development, regulatory and clinical affairs, quality assurance, manufacturing and commercialization.
Over 25 years in med devices/IVD with people management experience.
Former CSO Agilent Technologies, Companion Diagnostics.
Invited guest speaker, Personalized Medicine, Regulatory/Clinical and IVD conferences.
12 issued patents.
Board Director with two non-profit organizations.
Kelly Christian, MS
R&D and Engineering
30 years bringing new medical devices to market.
20 years developing new chemo ports including developing the first PowerPort (TM).
Former Senior Director at Becton Dickinson as a biomedical engineer, team leader, and program director.
Launched products with an annual value of almost a billion dollars and improved outcomes for millions of patients worldwide.
30 issued patents related to ports.
Industrial Advisory Board Member for the school of Biomedical Engineering for the University of Utah.
Tufia Haddad, MD
Oncology, Product Advisor and
Board Chair, Investor Relations and Finance
Rich Nazarian, BS, MS
Engineering, Business Strategy and Partnerships
Serge Alexanian, MD
Surgical and Hospital Liaison
Nancy Lelicoff, MS
Engineering, Regulatory, Quality and Research
Digital Health Strategy and Investor Relations
Alan Feinerman, PhD
Research and Device Design
Vincent Kuenen, BS, MS
Engineering, Software Development and Patient Advocate